Gilead Sciences stock gains a new signal from lenacapavir data

Gilead Sciences added a concrete HIV prevention result to the pipeline debate on Friday, November 6, as the company released one-year PURPOSE 5 data ahead of presentations at HIV Glasgow. The study showed that twice-yearly lenacapavir kept more participants on PrEP than daily oral F/TDF, according to Gilead Sciences.

Persistence becomes the key pipeline signal

At Week 52, 85.6 percent of participants receiving twice-yearly lenacapavir remained persistent on PrEP, compared with 46.3 percent for daily F/TDF. The difference was statistically significant, and no HIV acquisitions occurred among participants receiving lenacapavir during the study period.

The Phase 2 trial enrolled people in the United Kingdom and France who were not taking PrEP at enrollment. Gilead said one HIV acquisition occurred in the F/TDF group, with drug-level analysis consistent with fewer than two doses per week at diagnosis.

The safety profile was broadly consistent with earlier studies. Serious adverse events occurred in 3.9 percent of participants receiving lenacapavir and 3.4 percent of those receiving F/TDF, while injection-site reactions were the most common treatment-related events for lenacapavir.

HIV Glasgow adds the next catalyst

HIV Glasgow runs from Sunday, November 8, through Wednesday, November 11. Gilead is presenting more than 50 studies spanning prevention, treatment and cure research, including results on lenacapavir, Biktarvy, the investigational once-weekly islatravir-lenacapavir combination and GS-3242.

The PURPOSE 5 results strengthen the commercial case for less frequent dosing, but they do not remove clinical, regulatory, pricing or market-access risks. For investors, the conference offers evidence on persistence and treatment preferences rather than a confirmed near-term revenue contribution.

Gilead Sciences stock traded at 150.43 euros on Lang & Schwarz at 16:01 CET on Monday, November 9, 0.18 percent above the Xetra close of Friday, November 6. The comparison uses the last completed Xetra session because the European trading day had not reached the evening close threshold.

US biotechnology shares remain exposed to clinical data and regulatory headlines; broader market developments are covered in current S&P 500 market reports.

Further developments can be followed through More news and analyses on Gilead Sciences stock.